| pubmed-article:7779724 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C0950521 | lld:lifeskim |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:7779724 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:7779724 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:7779724 | pubmed:dateCreated | 1995-7-19 | lld:pubmed |
| pubmed-article:7779724 | pubmed:abstractText | The aim of this study was to test the hypothesis of Goldie and Coldman that the use of non-cross-resistant regimens of chemotherapy could lead to maximal anti-tumour effect. We compared standard CMF (cyclophosphamide, methotrexate, fluorouracil) with alternating CMF/EV (epirubicin, vincristine) in the adjuvant therapy of early breast cancer. Stage II premenopausal node-positive or post-menopausal node-positive oestrogen receptor-negative and stage III breast cancer patients were eligible for the study. From January 1985 to December 1990, 220 patients were randomised (115 to CMF and 105 to CMF/EV). Toxicity was mild; neurotoxicity, vomiting and hair loss were more frequent in the CMF/EV group, while permanent amenorrhoea, diarrhoea, stomach ache and minor infections occurred more often in the CMF arm. At a follow-up of 48 months, 113 patients (51.4%) had had recurrence (62 on CMF and 51 on CMF/EV) and 54 (24.5%) had died (30 on CMF and 24 on CMF/EV). There was no significant difference in disease-free and overall survival between the two arms. After adjusting for menopausal status and stage, the relative risk (RR) of recurrence for CMF/EV patients was 0.93 (95% CL 0.64-1.35), while the RR of death was 0.85 (95% CL 0.49-1.47). In conclusion, the Goldie-Coldman model of alternating therapy is not confirmed in this trial of adjuvant therapy of early breast cancer, although in view of its design a difference of less than 20% in 3 year disease-free survival could not be excluded. | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7779724 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7779724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7779724 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7779724 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:7779724 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:PetrellaGG | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:MarinelliAA | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:MorabitoAA | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:De PlacidoSS | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:PerroneFF | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:LauriaRR | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:PagliaruloCC | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:CarlomagnoCC | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:7779724 | pubmed:author | pubmed-author:VarrialeEE | lld:pubmed |
| pubmed-article:7779724 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7779724 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:7779724 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7779724 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:7779724 | pubmed:pagination | 1283-7 | lld:pubmed |
| pubmed-article:7779724 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:meshHeading | pubmed-meshheading:7779724-... | lld:pubmed |
| pubmed-article:7779724 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7779724 | pubmed:articleTitle | CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). | lld:pubmed |
| pubmed-article:7779724 | pubmed:affiliation | Division of Medical Oncology, School of Medicine, University of Naples Federico II, Italy. | lld:pubmed |
| pubmed-article:7779724 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7779724 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7779724 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7779724 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7779724 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7779724 | lld:pubmed |
